Corporate News
Daiichi Sankyo has entered into a partnership with Innovent Biologics to commercialise the FLT3‑inhibitor therapy Vanflyta in China. Under the agreement, the Japanese company will handle the development, manufacturing and supply of the drug, while Innovent will retain exclusive rights to market it within the mainland market. Vanflyta, approved earlier this year for use in combination with standard chemotherapy regimens and as maintenance therapy for adults newly diagnosed with FLT3‑ITD positive acute myeloid leukaemia, represents a significant addition to the therapeutic options available to patients in China.
The collaboration is positioned to accelerate patient access to the medication, leveraging Daiichi Sankyo’s manufacturing capabilities and Innovent’s established commercial presence in the Chinese oncology sector. Both parties highlighted the potential to improve outcomes for a high‑risk patient population, noting the drug’s strong clinical profile demonstrated in the QuANTUM‑First trial. The deal underscores the growing trend of cross‑border collaborations aimed at expanding the reach of targeted oncology therapies in key emerging markets.
Daiichi Sankyo, which focuses heavily on oncology and antibody‑drug conjugates, stated that the partnership aligns with its broader strategy of delivering innovative treatments worldwide. Innovent Biologics, with a growing portfolio of biopharmaceutical products, described the alliance as a milestone that will enhance its market footprint and reinforce its leadership in cancer therapeutics.
The agreement does not appear to introduce new regulatory hurdles, as the product has already received approval in China for the specified indications. Market analysts anticipate that the collaboration will strengthen Daiichi Sankyo’s commercial footprint in the region and provide a more robust pipeline for addressing acute myeloid leukaemia, a disease with substantial unmet needs.
